Anika Therapeutics appoints Steve Griffin CEO effective Feb 1, 2026; Cheryl Blanchard becomes Executive Chair

Anika Therapeutics, Inc.

Steve Griffin, current CFO & COO, promoted to President and CEO effective Feb 1, 2026.
Cheryl Blanchard transitions from CEO to Executive Chair for 12 months, then Special Advisor.
Reaffirmed FY2025 guidance: Commercial Channel $47-49.5M (+12-18% YoY), OEM $62-65M (-16-20% YoY).
Director Susan Vogt resigns effective Feb 1, 2026; no disagreements with the Company.
Griffin receives $690k base salary, 75% target bonus, and $2.45M equity grant vesting over three years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.